Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis : Danish nationwide register-based study
Copyright © 2024. Published by Elsevier España, S.L.U..
INTRODUCTION AND OBJECTIVES: Studies on the societal burden of patients with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD) are sparse. This study examined this question, comparing NAFLD with matched reference groups.
MATERIALS AND METHODS: Nationwide Danish healthcare registers were used to include all patients (≥18 years) diagnosed with biopsy-verified NAFLD (1997-2021). Patients were classified as having simple steatosis or non-alcoholic steatohepatitis (NASH) with or without cirrhosis, and all matched with liver-disease free reference groups. Healthcare costs and labour market outcomes were compared from 5 years before to 11 years after diagnosis. Patients were followed for 25 years to analyse risk of disability insurance and death.
RESULTS: 3,712 patients with biopsy-verified NASH (n = 1,030), simple steatosis (n = 1,540) or cirrhosis (n = 1,142) were identified. The average total costs in the year leading up to diagnosis was 4.1-fold higher for NASH patients than the reference group (EUR 6,318), 6.2-fold higher for cirrhosis patients and 3.1-fold higher for simple steatosis patients. In NASH, outpatient hospital contacts were responsible for 49 % of the excess costs (EUR 3,121). NASH patients had statistically significantly lower income than their reference group as early as five years before diagnosis until nine years after diagnosis, and markedly higher risk of becoming disability insurance recipients (HR: 4.37; 95 % CI: 3.17-6.02) and of death (HR: 2.42; 95 % CI: 1.80-3.25).
CONCLUSIONS: NASH, simple steatosis and cirrhosis are all associated with substantial costs for the individual and the society with excess healthcare costs and poorer labour market outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Annals of hepatology - 29(2024), 3 vom: 23. Jan., Seite 101285 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rudolfsen, Jan Håkon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burden of disease |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.aohep.2024.101285 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367625962 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367625962 | ||
| 003 | DE-627 | ||
| 005 | 20240217232322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.aohep.2024.101285 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM367625962 | ||
| 035 | |a (NLM)38272183 | ||
| 035 | |a (PII)S1665-2681(24)00002-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rudolfsen, Jan Håkon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis |b Danish nationwide register-based study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier España, S.L.U. | ||
| 520 | |a INTRODUCTION AND OBJECTIVES: Studies on the societal burden of patients with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD) are sparse. This study examined this question, comparing NAFLD with matched reference groups | ||
| 520 | |a MATERIALS AND METHODS: Nationwide Danish healthcare registers were used to include all patients (≥18 years) diagnosed with biopsy-verified NAFLD (1997-2021). Patients were classified as having simple steatosis or non-alcoholic steatohepatitis (NASH) with or without cirrhosis, and all matched with liver-disease free reference groups. Healthcare costs and labour market outcomes were compared from 5 years before to 11 years after diagnosis. Patients were followed for 25 years to analyse risk of disability insurance and death | ||
| 520 | |a RESULTS: 3,712 patients with biopsy-verified NASH (n = 1,030), simple steatosis (n = 1,540) or cirrhosis (n = 1,142) were identified. The average total costs in the year leading up to diagnosis was 4.1-fold higher for NASH patients than the reference group (EUR 6,318), 6.2-fold higher for cirrhosis patients and 3.1-fold higher for simple steatosis patients. In NASH, outpatient hospital contacts were responsible for 49 % of the excess costs (EUR 3,121). NASH patients had statistically significantly lower income than their reference group as early as five years before diagnosis until nine years after diagnosis, and markedly higher risk of becoming disability insurance recipients (HR: 4.37; 95 % CI: 3.17-6.02) and of death (HR: 2.42; 95 % CI: 1.80-3.25) | ||
| 520 | |a CONCLUSIONS: NASH, simple steatosis and cirrhosis are all associated with substantial costs for the individual and the society with excess healthcare costs and poorer labour market outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Burden of disease | |
| 650 | 4 | |a Cost | |
| 650 | 4 | |a Non-alcoholic steatohepatitis | |
| 650 | 4 | |a Real-world data | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Gluud, Lise Lotte |e verfasserin |4 aut | |
| 700 | 1 | |a Grønbæk, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Majken K |e verfasserin |4 aut | |
| 700 | 1 | |a Vyberg, Mogens |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Bo Poulsen, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Hovelsø, Nanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gregersen, Nikolaj Ture |e verfasserin |4 aut | |
| 700 | 1 | |a Thomsen, Anne Bloch |e verfasserin |4 aut | |
| 700 | 1 | |a Jepsen, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hepatology |d 2002 |g 29(2024), 3 vom: 23. Jan., Seite 101285 |w (DE-627)NLM14740004X |x 1665-2681 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:3 |g day:23 |g month:01 |g pages:101285 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.aohep.2024.101285 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 3 |b 23 |c 01 |h 101285 | ||